SmartTab CEO Participates in Oral Biologics Discussion Group at Formulation & Delivery UK
By Sacha Heppell - September 09, 2021
SmartTab Founder and CEO, Robert Niichel was invited to join a discussion group on "Oral Delivery of Biologics", bioavailability and the what the future look like for orally available biologics. This was part of the Formulation & Delivery UK Conference that SmartTab is attending as part of a delegation from Denver, Colorado to London Tech Week.
Biologics-based medicines are an extremely promising avenue for therapeutics. Given their size, they are extremely sensitive once they enter the gastrointestinal system. For the launch of Oxford Global’s first Formulation & Drug Delivery Discussion Group, we are bringing together thought-leaders discussing the oral delivery of biologics; with an in-depth discussion pertaining to their permeability and bioavailability and explore which drugs are fit to be delivered orally emphasizing the importance of knowing the therapeutic area to target.
The program started with a presentation on the Current Landscape Of Orally Delivered Biologics. Then entered a panel discussion on Oral Delivery of Biologics, Current Challenges & Opportunities. Looking at commercial drivers & demand, bioavailability, getting the biologics through the membrane in a sufficient way, including permeability and what the future looks like for orally available biologics.
Patrick Garidel, Head of Process, Purification and Pharma Development, Biopharma, Boehringer Ingelheim
Shawn Davies, Head of Drug Delivery, BioPharmaceuticals Development, R&D, AstraZeneca Joel Richard, Chief Technology Officer, Medincell Robert, Founder & Chief Executive Officer, SmartTab